In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uluru Inc.

www.uluruinc.com

Latest From Uluru Inc.

Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping the Medical Industry (09/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Dr Jeffrey Stone joins Uluru's board

Dr Jeffrey Stone has joined the board of directors at Uluru, a US speciality pharmaceutical company developing a portfolio of wound management and oral care products. Dr Stone is president of Wound Care Consultants and is a past president Texas affiliate of the American Diabetes Association.

Metabolic Disorders Dermatology

Market Insight - Rich pickings from reformulations?

In recent years, drug reformulation has emerged as a popular defence strategy among pharmaceutical companies seeking to prolong the life cycles of their best-selling products. It has also attracted growing interest from specialist companies developing novel formulations of off-patent drugs and which either launch them as replacements for the originator products, or reposition them for new indications.

Gastrointestinal Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Dental & Oral Products
  • Neurology, Nervous System
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Uluru Inc.
  • Senior Management
  • Helmut Kerschbaumer , Interim Pres. & CEO
    Terrance Wallberg, VP, CFO
  • Contact Info
  • Uluru Inc.
    Phone: (214) 905-5145
    4452 Beltway Dr.
    Addison, TX 75001
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register